Case Report: Strongyloidiasis Refractory to Treatment with Ivermectin

American Journal of the Medical Sciences

Volumn 311, Issue 4, 1996, Pages 178-179

  Ashraf, Muhammad ^a   Gue, Crystal L ^a   Baddour, Larry M ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Hypogammaglobulinemia; Ivermectin; Refractory; Strongyloidiasis; Thiabendazole

Indexed keywords

ANTINEMATODAL AGENT; IVERMECTIN; TIABENDAZOLE;

ADULT; AGAMMAGLOBULINEMIA; ANIMAL; ARTICLE; CASE REPORT; DRUG RESISTANCE; FEMALE; HUMAN; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; CHRONIC DISEASE; HYPOGAMMAGLOBULINEMIA; TREATMENT FAILURE;

ADULT; AGAMMAGLOBULINEMIA; ANIMALS; ANTINEMATODAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; IVERMECTIN; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS;

EID: 0030117258     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199604000-00005     Document Type: Article

References (17)

1. Genta RM. Global prevalence of Strongyloidiasis: Critical review with epidemiological insights into the prevention of disseminated disease. Rev Infect Dis. 1989;11:755-67.
2. Junod C. Etude retrospective de 1934 cas de strongyloidose diagnostiques a Paris (1970-1986). Oigine Geographique. Epidemiologie. Bull Soc Pathol Exot. 1987;80:357-69.
3. Fulmer HS, Huempfner HR. Intestinal helminths in eastern Kentucky: A survey in three rural counties. Am J Trop Med Hyg. 1965;14:269-75.
4. Walzer PD, Milder JE, Banwell JG, Kilgore G, Klein M, Parker R. Epidemiological features of Strongyoides stercoralis infection in an endemic area of the United States. Am J Trop Med Hyg. 1982;31:313-9.
5. Berk SL, Verghese A, Alvarez S, Hall K, Smith B. Clinical and epidemiological features of strongyloidiasis: A prospective study in rural Tennessee. Arch Intern Med. 1987;147:1257-61.
6. Kramer MR, Gregg PA, Goldstein M, Llamas R, Krieger BP. Disseminated strongyloidiasis in AIDS and non-AIDS immunocompromised hosts: Diagnosis by sputum and bronchoalveolar lavage. South Med J. 1990;83:1226-9.
7. Williams BT, Guerry-Force ML. Disseminated strongyloidiasis in a World War II veteran with metastatic undifferentiated carcinoma of neuroendocrine type. South Med J. 1992;85:1023-6.
8. Chaudhary K, Smith RJ, Himelright IM, Baddour LM. Case report: Purpura in disseminated strongyloidiasis. Am J Med Sci. 1994;308:186-91.
9. Harcourt-Webster JN, Scaravilli F, Darwish AH. Strongyloides stercoralis hyperinfection in an HIV positive patient. J Clin Pathol. 1991;44:346-8.
10. Lessnau K, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of literature. Chest. 1993;104: 119-22.
11. Kaslow JE, Novey HS, Zuch RH, Spear GS. Disseminated strongyloidiasis: An unheralded risk of corticosteroid therapy. J Allergy Clin Immunol. 1990;86:138.
12. Tabacof J, Feher O, Katz A, Simon SD, Gansl RC. Strongyloides hyperinfection in two patients with lymphoma, purulent meningitis, and sepsis. Cancer. 1991;68:1821-3.
13. Dutcher JP, Marcus SL, Tanowitz HB, Wittner M, Fuks JZ, Wiernik PH. Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer. 1990;66:2417-20.
14. Goa KL, McTavish D, Clissold SP. Ivermectin. A review of its antiflarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. 1991;42:640-58.
15. Campbell WC, Fisher MH, Stapley EO, Albers-Schonberg G, Jacob TA. Ivermectin: A potent new antiparasitic agent. Science. 1983;221:823-8.
16. Torres JR, Isturiz R, Murillo J, Guzman M, Contreras R. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis. 1993;17:900-2.
17. Gann PH, Neva FA, Gam AA. A randomized trail of single-and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis. 1994;169:1076-9.